Ascelia Pharma announces today that results of the Phase I study for Oncoral has been accepted as a poster presentation at the European Society for Medical Oncology (ESMO) Annual Congress in Munich, Germany, 19-23 October 2018.
The presentation covers the part of the study where Oncoral has been given as single agent. An abstract for the presentation will be published online via the EMSO website on 9 October 2018.
About the Phase I study:
Oncoral has been evaluated in an investigator sponsored Phase I trial at the Department of Oncology at Herlev Hospital in Denmark. The study was a dose-escalating safety, tolerability and pharmacokinetics study of orally administered Oncoral in adult patients with advanced solid tumours. The objectives of the study were to determine the safety, tolerability and maximum tolerated dose of Oncoral given as single agent and when administered in combination with the oral chemotherapeutic drug capecitabine. Additional objectives were to determine any objective tumour response or stable disease, and to describe the pharmacokinetics of Oncoral given as single agent. A total of 25 patients were enrolled in the part of the study with Oncoral given as single agent.
The results of the combination study with capecitabine will be presented at a later stage.
For further information contact:
Magnus Corfitzen, CEO, +46 735 179 110
About Ascelia Pharma
Ascelia Pharma is a specialty pharmaceutical company dedicated to the development of novel medicines to improve the life expectancy and quality of life for people living with cancer. The company is located at Medeon Science Park in Malmö, Sweden in the middle of Medicon Valley, a leading European life science cluster. For more information, please visit www.ascelia.com